Human Papillomavirus (HPV) High/Low Risk, In Situ Hybridization
Use
The test is used to detect human papillomavirus (HPV) genotypes that are associated with both low-risk and high-risk conditions. Low-risk genotypes such as HPV 6 and 11 are linked to benign hyperplasias like condylomas and papillomas. On the other hand, high-risk genotypes (including but not limited to HPV 16, 18, and others) are linked to cervical, vaginal, vulvar, and head and neck malignancies. These include HPV-related oropharyngeal squamous cell carcinoma (OPSCC), where patients often exhibit better disease-specific survival and overall survival compared to those with HPV-negative OPSCC.
Special Instructions
Not provided.
Limitations
Stability of cut paraffin sections may affect staining quality, with best practices suggesting sections be cut within 6 weeks. The results are reported as positive or negative for low-risk types 6 and 11, and high-risk types listed in the test description. This test is not meant for follow-up on previously diagnosed HPV nor should it replace traditional methods of HPV testing.
New York Approved
Methodology
Chromosomal / Cytogenetics (ISH)
Biomarkers
Unknown microorganism
Microorganism
LOINC Codes
- 50595-8
- 81178-6
- 62364-5
- 80398-1
- 19139-5
Result Turnaround Time
5-7 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Entire block
Minimum Volume
Not provided
Causes for Rejection
Wet/frozen tissue, Cytology smears, Nonformalin fixed tissue, Nonparaffin embedded tissue, Noncharged slides, ProbeOn slides
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Ambient (preferred) |